Abstract:Alopecia areata (AA) is an autoimmune disorder characterized by nonscarring hair loss.1 Numerous treatment options are available for AA.2, 3 However, it is often challenging and unsatisfactory for refractory AA treatment. Recently, Janus kinase inhibitors (JAKis) have shown promising results in treating AA.4 For example, baricitinib has shown good clinical efficacy in two phase 3 trials involving patients with severe AA.5 Here we present a case series of 11 patients with refractory AA treated with baricitinib. The Ethics Committee of The First Affiliated Hospital, Zhejiang University School of Medicine (Approved number: IIT2022089) approved this study. The following clinical characteristics were collected: age, sex, age at AA onset, disease duration, clinical type, previous treatment, and comorbidities. At each visit, symptom-directed physical examination and clinical laboratory tests were conducted. All patients received at least one therapy for more than 1 year, including minoxidil, oral/topical/intralesional steroid, phototherapy, acupuncture, or herbal medicine prior to the initiation of baricitinib; however, the response was poor. All patients received baricitinib 2 mg twice daily for 20 weeks. Meanwhile, patients also used topical minoxidil as adjuvant therapy. The Severity of Alopecia Tool (SALT) was used to assess alopecia severity. SALT25, SALT50, and SALT75 were defined as 25%, 50%, and 75% regrowth, respectively. The results were divided into the following three categories: (I) “complete response” (CR), hair growth coexisted with no obvious plaques of hair loss; (II) “partial response” (PR), hair growth coexisted with obvious plaques; and (III) “no response” (NR), no hair growth. Adverse events were also recorded. The results are summarized in Table 1. The subtypes of AA included alopecia universalis in two patients, alopecia totalis in two patients, multiple AA in six patients, and alopecia ophiasis in one patient. The median age at the beginning of AA was 17 (range, 3–14) and the median baseline SALT score was 54% (range, 32%–100%). Seven patients (64%) had nail involvement and five (45%) patients had total or partial body hair loss. At week 20, two patients (18%) achieved CR, six patients (55%) achieved PR, and three patients (27%) were evaluated as NR. Nine patients responded positively to baricitinib treatment, one of whom subsequently lost regenerated hair, while the other two patients experienced no regrowth. The median SALT score was 15% (range, 3%–100%) and the median percent change in SALT score was 34% (range, 0%–83%) at week 20. Our results showed that seven patients (64%), three patients (27%), and two patients (18%) achieved SALT25, SALT50, and SALT75, respectively, while none of them achieved complete hair regrowth. Representative photos of two patients who had a typical response to baricitinib therapy are presented in Figure 1. Adverse events were mild and limited to nausea (n = 1), folliculitis (n = 2), and mild increases in liver transaminase levels (n = 1). A meta-analysis estimated that 72.4% of patients with AA responded to JAKis.6 Furthermore, one phase 2 trial7 and two phase 3 trials5 demonstrated that baricitinib 4 mg once daily proved beneficial over the 2-mg dose. In our study, 27% achieved SALT50 with twice-daily oral baricitinib at a 2-mg dose, which is a remarkable finding because most patients had refractory AA. This series included only Chinese patients and they received a different dose of baricitinib because some patients were unable to tolerate the gastrointestinal reactions at a 4-mg dose once daily. Further investigations are needed in the future to explore whether this difference in baricitinib response is due to ethnic or environmental differences. Moreover, numerous studies described an increased serum level of IL-6 and IL-17A in patients with AA.8, 9 Indeed, serum level of IL-6 and IL-17A was significantly elevated in 54.5% of all patients at the baseline in our study. After treatment with baricitinib, both levels returned to normal. In summary, in our study, baricitinib is efficacious in refractory AA treatment. To determine the safety and efficacy of baricitinib for AA, further trials are warranted. Study design: Yuqian Wang, Jianjun Qiao, Hong Fang. Data collection: Yuqian Wang, Taoming Liu, Sheng Li, Shunli Tang, Peiyi Lin, Yuwei Ding. Statistical analysis: Yuqian Wang. Data interpretation: Qingmiao Sun, Dingxian Zhu. Manuscript preparation: Yuqian Wang, Jianjun Qiao, Hong Fang. The authors wish to thank all patients who took part in this study. The patients in this manuscript have given written informed consent for publication of their case details. This study was supported by the National Natural Science Foundation of China (81972931 and 81673045 to HF). The authors have no conflicts to disclose in relation to the present study. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Pharmacokinetics, Safety, and Tolerability of Single- and Multiple-Dose Once-Daily Baricitinib in Healthy Chinese Subjects: A Randomized Placebo-Controlled Study.

Safety, tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid X receptor (FXR) agonist-TQA3526 in healthy Chinese volunteers: a double-blind, randomized, placebo-controlled, dose-escalation, food effect phase I study

Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE.

Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE

Short-term Effectiveness of Baricitinib in Children with Refractory And/or Severe Juvenile Dermatomyositis.

Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 Mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study

A double-blind pilot study of oral baricitinib in adult patients with lupus erythematosus panniculitis

32333 Clinical and Pharmacokinetic Results of Upadacitinib in Chinese Healthy Subjects and Subjects with Moderate-to-severe Atopic Dermatitis

P1594: BARICITINIB FOR STEROID-RESISTANT/RELAPSE IMMUNE THROMBOCYTOPENIA (BAITP): AN OPEN-LABEL, SINGLE-ARM, PHASE 2 TRIAL

Pooled Analysis of Baricitinib Tolerability in Patients With Atopic Dermatitis in Relation to Acne, Headache, and Gastrointestinal Events From 8 Clinical Trials

Patient-reported Outcomes from a Randomized, Double-Blind, Placebo Controlled, Phase III Study of Baricitinib Versus Placebo in Patients with Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Therapy: Results from the RA-BALANCE Study

Efficacy and safety of baricitinib in the treatment of moderate-to-severe atopic dermatitis: a clinical observation

Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials

Baricitinib in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: Results from a Phase 3 Study.

Efficacy and Safety of Baricitinib in Patients with Refractory Alopecia Areata

Baricitinib for the treatment of intestinal Behçet's disease: A pilot study

Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis

SAT0253 Dose Reduction of Baricitinib in Patients with Rheumatoid Arthritis Achieving Sustained Disease Control: Results of a Prospective Study

Pharmacokinetics and Tolerability of Intravenous Ibuprofen Injection in Healthy Chinese Volunteers: a Randomized, Open-Label, Single- and Multiple-Dose Study

Efficacy and safety of baricitinib in combination with topical corticosteroids in pediatric patients with moderate-to-severe atopic dermatitis with inadequate response to topical corticosteroids: results from a phase 3, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS)

Safety and efficacy of baricitinib in steroid-resistant or relapsed immune thrombocytopenia: An open-label pilot study